Essential role of the unordered VP2 n-terminal domain of the parvovirus MVM capsid in nuclear assembly and endosomal enlargement of the virion fivefold channel for cell entry

Virology

Volumn 432, Issue 1, 2012, Pages 45-56

  Sánchez Martínez, Cristina ^a,d   Grueso, Esther ^a,e   Carroll, Miles ^c   Rommelaere, Jean ^b   Almendral, José M ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d Inbiomed Foundation   (Spain)

^e PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Assembly; Capsid cleavage; Cell entry; Parvovirus; Peptide insertion; Virus traffick

Indexed keywords

PEPTIDE; PROTEIN VP1; PROTEIN VP2;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CELL NUCLEUS; CHIMERA; EMBRYO; ENDOSOME; GENE INSERTION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PARVOVIRUS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN FUNCTION; VIRION; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS ENTRY; VIRUS INFECTIVITY;

ANIMALS; CAPSID PROTEINS; CELL LINE; CELL NUCLEUS; ENDOSOMES; MICE; MINUTE VIRUS OF MICE; MODELS, BIOLOGICAL; PROTEIN STRUCTURE, TERTIARY; VIRUS ASSEMBLY; VIRUS INTERNALIZATION;

MIRIDAE; PARVOVIRUS;

EID: 84863996513     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.05.025     Document Type: Article

References (81)

1. Agbandje-McKenna M., Llamas-Saiz A.L., Wang F., Tattersall P., Rossmann M.G. Functional implications of the structure of the murine parvovirus, minute virus of mice. Structure 1998, 6:1369-1381.
2. Asokan A., Conway J.C., Phillips J.L., Li C., Hegge J., Sinnott R., Yadav S., DiPrimio N., Nam H.J., Agbandje-McKenna M., McPhee S., Wolff J., Samulski R.J. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat. Biotechnol. 2010, 28:79-82.
3. Astell C.R., Gardiner E.M., Tattersall P. DNA sequence of the lymphotropic variant of minute virus of mice, MVM(i), and comparison with the DNA sequence of the fibrotropic prototype strain. J. Virol. 1986, 57:656-669.
4. Binetruy-Tournaire R., Demangel C., Malavaud B., Vassy R., Rouyre S., Kraemer M., Plouet J., Derbin C., Perret G., Mazie J.C. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. Embo J. 2000, 19:1525-1533.
5. Bleker S., Sonntag F., Kleinschmidt J.A. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J. Virol. 2005, 79:2528-2540.
6. Boisvert M., Fernandes S., Tijssen P. Multiple pathways involved in porcine parvovirus cellular entry and trafficking toward the nucleus. J. Virol. 2010, 84:7782-7792.
7. Bonsch C., Zuercher C., Lieby P., Kempf C., Ros C. The globoside receptor triggers structural changes in the B19 virus capsid that facilitate virus internalization. J. Virol. 2010, 84:11737-11746.
8. Carreira A., Menendez M., Reguera J., Almendral J.M., Mateu M.G. In vitro disassembly of a parvovirus capsid and effect on capsid stability of heterologous peptide insertions in surface loops. J. Biol. Chem. 2004, 279:6517-6525.
9. Chandran K., Farsetta D.L., Nibert M.L. Strategy for nonenveloped virus entry: a hydrophobic conformer of the reovirus membrane penetration protein μ1 mediates membrane disruption. J. Virol. 2002, 76:9920-9933.
10. Cotmore S.F., D'Abramo A., Ticknor M., Tattersall, P.C.M. Controlled conformational transitions in the MVM virion expose the VP1 N-terminus and viral genome without particle disassembly. Virology 1999, 254:169-181.
11. Cotmore S.F., Tattersall P. Encapsidation of minute virus of mice DNA: aspects of the translocation mechanism revealed by the structure of partially packaged genomes. Virology 2005, 336:100-112.
12. Cotmore S.F., Tattersall P. Parvoviral host range and cell entry mechanisms. Adv. Virus Res. 2007, 70:183-232.
13. Cotmore S.F., Hafenstein S., Tattersall P. Depletion of virion-associated divalent cations induces parvovirus minute virus of mice to eject its genome in a 3'-to-5'direction from an otherwise intact viral particle. J. Virol. 2010, 84:1945-1956.
14. Farr G.A., Cotmore S.F., Tattersall P. VP2 cleavage and the leucine ring at the base of the fivefold cylinder control pH-dependent externalization of both the VP1 N terminus and the genome of minute virus of mice. J. Virol. 2006, 80:161-171.
15. Farr G.A., Tattersall P. A conserved leucine that constricts the pore through the capsid fivefold cylinder plays a central role in parvoviral infection. Virology 2004, 323:243-256.
16. Farr G.A., Zhang L.G., Tattersall P. Parvoviral virions deploy a capsid-tethered lipolytic enzyme to breach the endosomal membrane during cell entry. Proc. Natl. Acad. Sci. USA 2005, 102:17148-17153.
17. Fritsche R., Mach J. Identification of a new oncofoetal antigen associated with several types of human carcinomas. Nature 1975, 258:734-737.
18. Gardiner E.M., Tattersall P. Mapping of the fibrotropic and lymphotropic host range determinants of the parvovirus minute virus of mice. J. Virol. 1988, 62:2605-2613.
19. Girod A., Ried M., Wobus C., Lahm H., Leike K., Kleinschmidt J., Deleage G., Hallek M. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat. Med. 1999, 5:1438.
20. Girod A., Wobus C.E., Zadori Z., Ried M., Leike K., Tijssen P., Kleinschmidt J.A., Hallek M. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J. Gen. Virol. 2002, 83:973-978.
21. Gurda B.L., Parent K.N., Bladek H., Sinkovits R.S., DiMattia M.A., Rence C., Castro A., McKenna R., Olson N., Brown K., Baker T.S., Agbandje-McKenna M. Human bocavirus capsid structure: insights into the structural repertoire of the parvoviridae. J. Virol. 2010, 84:5880-5889.
22. Hammond A.L., Plemper R.K., Zhang J., Schneider U., Russell S.J., Cattaneo R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J. Virol. 2001, 75:2087-2096.
23. Hernando E., Llamas-Saiz A.L., Foces-Foces C., McKenna R., Portman I., Agbandje-McKenna M., Almendral J.M. Biochemical and physical characterization of parvovirus minute virus of mice virus-like particles. Virology 2000, 267:299-309.
24. Hurtado A., Rueda P., Nowicky J., Sarraseca J., Casal J.I. Identification of domains in canine parvovirus VP2 essential for the assembly of virus-like particles. J. Virol. 1996, 70:5422-5429.
25. Johnson J.S., Li C., DiPrimio N., Weinberg M.S., McCown T.J., Samulski R.J. Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J. Virol. 2010, 84:8888-8902.
26. Jongeneel C.V., Sahli R., McMaster G.K., Hirt B. A precise map of splice junctions in the mRNAs of minute virus of mice, an autonomous parvovirus. J. Virol. 1986, 59:564-573.
27. Kashentseva E.A., Seki T., Curiel D.T., Dmitriev I.P. Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res. 2002, 62:609-616.
28. Kaufmann B., Chipman P.R., Kostyuchenko V.A., Modrow S., Rossmann M.G. Visualization of the externalized VP2 N termini of infectious human parvovirus B19. J. Virol. 2008, 82:7306-7312.
29. Kaufmann B., Lopez-Bueno A., Mateu M.G., Chipman P.R., Nelson C.D., Parrish C.R., Almendral J.M., Rossmann M.G. Minute virus of mice, a parvovirus, in complex with the Fab fragment of a neutralizing monoclonal antibody. J. Virol. 2007, 81:9851-9858.
30. Kaufmann B., Simpson A.A., Rossmann M.G. The structure of human parvovirus B19. Proc. Natl. Acad. Sci. USA 2004, 101:11628-11633.
31. Kestler J., Neeb B., Struyf S., Van Damme J., Cotmore S.F., D'Abramo A., Tattersall P., Rommelaere J., Dinsart C., Cornelis J.J. cis requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses. Hum. Gene Ther. 1999, 10:1619-1632.
32. Kontou M., Govindasamy L., Nam H.J., Bryant N., Llamas-Saiz A.L., Foces-Foces C., Hernando E., Rubio M.P., McKenna R., Almendral J.M., Agbandje-McKenna M. Structural determinants of tissue tropism and in vivo pathogenicity for the parvovirus minute virus of mice. J. Virol. 2005, 79:10931-10943.
33. Lamikanra A., Myers K.A., Ferris N., Mitrophanous K.A., Carroll M.W. In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies. Gene Ther. 2005, 12:988-998.
34. Lang S.I., Boelz S., Stroh-Dege A.Y., Rommelaere J., Dinsart C., Cornelis J.J. The infectivity and lytic activity of minute virus of mice wild-type and derived vector particles are strikingly different. J.Virol. 2005, 79:289-298.
35. Lombardo E., Ramirez J.C., Agbandje-McKenna M., Almendral J.M. A beta-stranded motif drives capsid protein oligomers of the parvovirus minute virus of mice into the nucleus for viral assembly. J. Virol. 2000, 74:3804-3814.
36. Lombardo E., Ramirez J.C., Garcia J., Almendral J.M. Complementary roles of multiple nuclear targeting signals in the capsid proteins of the parvovirus minute virus of mice during assembly and onset of infection. J. Virol. 2002, 76:7049-7059.
37. Mani B., Baltzer C., Valle N., Almendral J.M., Kempf C., Ros C. Low pH-dependent endosomal processing of the incoming parvovirus minute virus of mice virion leads to externalization of the VP1 N-terminal sequence (N-VP1), N-VP2 cleavage, and uncoating of the full-length genome. J. Virol. 2006, 80:1015-1024.
38. Marin M., Noel D., Valsesia-Wittman S., Brockly F., Etienne-Julan M., Russell S., Cosset F.L., Piechaczyk M. Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J. Virol. 1996, 70:2957-2962.
39. Maroto B., Ramirez J.C., Almendral J.M. Phosphorylation status of the parvovirus minute virus of mice particle: mapping and biological relevance of the major phosphorylation sites. J. Virol. 2000, 74:10892-10902.
40. Maroto B., Valle N., Saffrich R., Almendral J.M. Nuclear export of the nonenveloped parvovirus virion is directed by an unordered protein signal exposed on the capsid surface. J. Virol. 2004, 78:10685-10694.
41. Maxwell I.H., Chapman J.T., Scherrer L.C., Spitzer A.L., Leptihn S., Maxwell F., Corsini J.A. Expansion of tropism of a feline parvovirus to target a human tumor cell line by display of an alpha(v) integrin binding peptide on the capsid. Gene Ther. 2001, 8:324-331.
42. Mercer J., Schelhaas M., Helenius A. Virus entry by endocytosis. Annu. Rev. Biochem. 2010, 79:803-833.
43. Merchlinsky M.J., Tattersall P.J., Leary J.J., Cotmore S.F., Gardiner E.M., Ward D.C. Construction of an infectious molecular clone of the autonomous parvovirus minute virus of mice. J. Virol. 1983, 47:227-232.
44. Morgan W.R., Ward D.C. Three splicing patterns are used to excise the small intron common to all minute virus of mice RNAs. J. Virol. 1986, 60:1170-1174.
45. Mulryan K., Ryan M.G., Myers K.A., Shaw D., Wang W., Kingsman S.M., Stern P.L., Carroll M.W. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol. Cancer Ther. 2002, 1:1129-1137.
46. Muller O.J., Kaul F., Weitzman M.D., Pasqualini R., Arap W., Kleinschmidt J.A., Trepel M. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat. Biotechnol. 2003, 21:1040-1046.
47. Odegard A.L., Kwan M.H., Walukiewicz H.E., Banerjee M., Schneemann A., Johnson J.E. Low endocytic pH and capsid protein autocleavage are critical components of Flock House virus cell entry. J. Virol. 2009, 83:8628-8637.
48. Paradiso P.R. Infectious process of the parvovirus H-1: correlation of protein content, particle density, and viral infectivity. J. Virol. 1981, 39:800-807.
49. Paradiso P.R., Williams K.R., Costantino R.L. Mapping of the amino terminus of the H-1 parvovirus major capsid protein. J. Virol. 1984, 52:77-81.
50. Parrish C.P. Structures and functions of parvovirus capsids and the process of cell infection. Curr. Top. Microbiol. Immunol. 2010, 343:149-176.
51. Plate K.H., Breier G., Weich H.A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359:845-848.
52. Plevka P., Susan Hafenstein S., Li L., D'Abramo A., Cotmore S.F., Rossmann M.G., Tattersall P. Structure of a packaging-defective mutant of minute virus of mice indicates that the genome is packaged via a pore at a 5-fold axis. J. Virol. 2011, 85:4822-4827.
53. Ramirez J.C., Santaren J.F., Almendral J.M. Transcriptional inhibition of the parvovirus minute virus of mice by constitutive expression of an antisense RNA targeted against the NS-1 transactivator protein. Virology 1995, 206:57-68.
54. Richards R.M., Lowy D.R., Schiller J.T., Day P.M. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl. Acad. Sci. USA 2006, 103:1522-1527.
55. Riolobos L., Reguera J., Mateu M.G., Almendral J.M. Nuclear transport of trimeric assembly intermediates exerts a morphogenetic control on the icosahedral parvovirus capsid. J. Mol. Biol. 2006, 357:1026-1038.
56. Riolobos L., Valle N., Hernando E., Maroto B., Kann M., Almendral J.M. Viral oncolysis that targets Raf-1 signaling control of nuclear transport. J. Virol. 2010, 84:2090-2099.
57. Rommelaere J., Geletneky K., Angelova A.L., Daeffler L., Dinsart C., Kiprianova I., Schlehofer J.R., Raykov Z. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev. 2010, 21:185-195.
58. Ros C., Burckhardt C.J., Kempf C. Cytoplasmic trafficking of minute virus of mice: low-pH requirement, routing to late endosomes, and proteasome interaction. J. Virol. 2002, 76:12634-12645.
59. Ros C., Gerber M., Kempf C. Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J. Virol. 2006, 80:12017-12024.
60. Rubio M.P., Lopez-Bueno A., Almendral J.M. Virulent variants emerging in mice infected with the apathogenic prototype strain of the parvovirus minute virus of mice exhibit a capsid with low avidity for a primary receptor. J. Virol. 2005, 79:11280-11290.
61. Rueda P., Hurtado A., del Barrio M., Martinez-Torrecuadrada J.L., Kamstrup S., Leclerc C., Casal J.I. Minor displacements in the insertion site provoke major differences in the induction of antibody responses by chimeric parvovirus-like particles. Virology 1999, 263:89-99.
62. Santaren J.F., Ramirez J.C., Almendral J.M. Protein species of the parvovirus minute virus of mice strain MVMp: involvement of phosphorylated VP-2 subtypes in viral morphogenesis. J. Virol. 1993, 67:5126-5138.
63. Sedlik C., Saron M., Sarraseca J., Casal I., Leclerc C. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl. Acad. Sci. USA 1997, 94:7503-7508.
64. Shaw D.M., Embleton M.J., Westwater C., Ryan M.G., Myers K.A., Kingsman S.M., Carroll M.W., Stern P.L. Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4. Biochim. Biophys. Acta 2000, 1524:238-246.
65. Sonntag F., Bleker S., Leuchs B., Fischer R., Kleinschmidt J.A. Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J. Virol. 2006, 80:11040-11054.
66. Tattersall P., Cawte P.J., Shatkin A.J., Ward D.C. Three structural polypeptides coded for by minute virus of mice, a parvovirus. J. Virol. 1976, 20:273-289.
67. Tattersall P., Shatkin A.J., Ward D.C. Sequence homology between the structural polypeptides of minute virus of mice. J. Mol. Biol. 1977, 111:375-394.
68. Tijssen, P., Agbandje-McKenna, M., Almendral, J.M., Bergoin, M., Flegel, T.W., Hedman, H., Kleinschmidt, J., Li, Y., Pintel, D.J., Tattersall, P., 2011. Family Parvoviridae, ICTV Ninth Report, pp. 405-425.
69. Tsai B. Penetration of nonenveloped viruses into the cytoplasm. Annu. Rev. Cell Dev. Biol. 2007, 23:23-43.
70. Tsao J., Chapman M.S., Agbandje M., Keller W., Smith K., Wu H., Luo M., Smith T.J., Rossmann M.G., Compans R.W., Parrish C.R. The three-dimensional structure of canine parvovirus and its functional implications. Science 1991, 251:1456-1464.
71. Tullis G.E., Burger L.R., Pintel D.J. The trypsin-sensitive RVER domain in the capsid proteins of minute virus of mice is required for efficient cell binding and viral infection but not for proteolytic processing in vivo. Virology 1992, 191:846-857.
72. Tullis G.E., Burger L.R., Pintel D.J. The minor capsid protein VP1 of the autonomous parvovirus minute virus of mice is dispensable for encapsidation of progeny single-stranded DNA but is required for infectivity. J. Virol. 1993, 67:131-141.
73. van Beusechem V.W., Grill J., Mastenbroek D.C., Wickham T.J., Roelvink P.W., Haisma H.J., Lamfers M.L., Dirven C.M., Pinedo H.M., Gerritsen W.R. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J. Virol. 2002, 76:2753-2762.
74. Vandenberghe L.H., Wilson J.M., Gao G. Tailoring the AAV vector capsid for gene therapy. Gene Ther. 2009, 16:311-319.
75. Vihinen-Ranta M., Wang D., Weichert W.S., Parrish C.R. The VP1 N-terminal sequence of canine parvovirus affects nuclear transport of capsids and efficient cell infection. J. Virol. 2002, 76:1884-1891.
76. Warrington K.H., Gorbatyuk O.S., Harrison J.K., Opie S.R., Zolotukhin S., Muzyczka N. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J. Virol. 2004, 78:6595-6609.
77. Weichert W.S., Parker J.S., Wahid A.T., Chang S.F., Meier E., Parrish C.R. Assaying for structural variation in the parvovirus capsid and its role in infection. Virology 1998, 250:106-117.
78. Xie Q., Bu W., Bhatia S., Hare J., Somasundaram T., Azzi A., Chapman M.S. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 2002, 99:10405-10410.
79. Yang Q., Mamounas M., Yu G., Kennedy S., Leaker B., Merson J., Wong-Staal F., Yu M., Barber J.R. Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Hum. Gene Ther. 1998, 9:1929-1937.
80. Yuan W., Parrish C.R. Canine parvovirus capsid assembly and differences in mammalian and insect cells. Virology 2001, 279:546-557.
81. Zadori Z., Szelei J., Lacoste M.C., Li Y., Gariepy S., Raymond P., Allaire M., Nabi I.R., Tijssen P. A viral phospholipase A2 is required for parvovirus infectivity. Dev. Cell 2001, 1:291-302.